bluebird bio Future Growth

Future criteria checks 2/6

bluebird bio is forecast to grow earnings and revenue by 49% and 41.5% per annum respectively. EPS is expected to grow by 62.5% per annum. Return on equity is forecast to be -21.5% in 3 years.

Key information

49.0%

Earnings growth rate

62.5%

EPS growth rate

Biotechs earnings growth	0%
Revenue growth rate	41.5%
Future return on equity	-21.5%
Analyst coverage	Good
Last updated	18 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BMV:BLUE * - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	311	-104	46	64	3
12/31/2025	247	-115	-179	-160	9
12/31/2024	71	-269	-315	-273	8
9/30/2024	53	-293	-271	-264	N/A
6/30/2024	55	-319	-254	-245	N/A
3/31/2024	46	-301	-248	-238	N/A
12/31/2023	29	-212	-244	-235	N/A
9/30/2023	22	-63	-209	-200	N/A
6/30/2023	9	-52	-236	-227	N/A
3/31/2023	4	-89	-276	-262	N/A
12/31/2022	4	-230	-329	-316	N/A
9/30/2022	5	-431	-447	-436	N/A
6/30/2022	6	-507	-525	-506	N/A
3/31/2022	5	-563	-574	-558	N/A
12/31/2021	4	-563	-659	-636	N/A
9/30/2021	-238	-573	-680	-651	N/A
6/30/2021	-220	-614	-678	-653	N/A
3/31/2021	-21	-480	-493	-468	N/A
12/31/2020	N/A	-561	-499	-470	N/A
9/30/2020	250	-642	-509	-474	N/A
6/30/2020	240	-653	-493	-439	N/A
3/31/2020	54	-828	-684	-616	N/A
12/31/2019	N/A	-555	-641	-564	N/A
9/30/2019	54	-715	-611	-535	N/A
6/30/2019	57	-655	-569	-496	N/A
3/31/2019	51	-605	-526	-459	N/A
12/31/2018	55	-556	-469	-413	N/A
9/30/2018	40	-524	-441	-379	N/A
6/30/2018	36	-457	N/A	-361	N/A
3/31/2018	45	-382	N/A	-314	N/A
12/31/2017	35	-336	N/A	-281	N/A
9/30/2017	33	-290	N/A	-254	N/A
6/30/2017	27	-288	N/A	-237	N/A
3/31/2017	11	-276	N/A	-228	N/A
12/31/2016	6	-264	N/A	-190	N/A
9/30/2016	6	-239	N/A	-154	N/A
6/30/2016	6	-205	N/A	-143	N/A
3/31/2016	9	-198	N/A	-111	N/A
12/31/2015	14	-167	N/A	-98	N/A
9/30/2015	19	-139	N/A	-81	N/A
6/30/2015	24	-113	N/A	-73	N/A
3/31/2015	25	-63	N/A	-72	N/A
12/31/2014	25	-49	N/A	-60	N/A
9/30/2014	25	-37	N/A	-49	N/A
6/30/2014	25	-26	N/A	-38	N/A
3/31/2014	25	-29	N/A	-35	N/A
12/31/2013	20	-25	N/A	43	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BLUE * is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BLUE * is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BLUE * is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BLUE *'s revenue (41.5% per year) is forecast to grow faster than the MX market (7.2% per year).

High Growth Revenue: BLUE *'s revenue (41.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BLUE * is forecast to be unprofitable in 3 years.

bluebird bio Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

Recent updates

Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.80 loss in 3Q 2023)

New major risk - Revenue and earnings growth

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

bluebird bio, Inc. announced delayed 10-Q filing

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

Chief Medical Officer recently sold Mex$176k worth of stock

Chief Medical Officer recently sold Mex$176k worth of stock

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

Less than half of directors are independent

Full year 2022 earnings released: US$3.39 loss per share (vs US$8.17 loss in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Less than half of directors are independent

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

Less than half of directors are independent

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

Treasurer recently sold Mex$1.6m worth of stock

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

President recently sold Mex$1.9m worth of stock

Second quarter 2022 earnings released: US$1.36 loss per share (vs US$2.31 loss in 2Q 2021)

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

Chief Regulatory Officer recently sold Mex$140k worth of stock

Less than half of directors are independent

bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Chief Commercial Officer recently sold Mex$226k worth of stock

Less than half of directors are independent

bluebird bio, Inc., Annual General Meeting, Jun 22, 2022

Bluebird Bio, Inc. Announces Executive Changes

bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022

bluebird bio, Inc. announced delayed annual 10-K filing

Less than half of directors are independent

bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer

Less than half of directors are independent

bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)

Insider recently sold Mex$80k worth of stock

bluebird bio, Inc. to Launch Both beti-cel and eli-cel for Patients in the U.S. in Mid-2022

Insider recently sold Mex$637k worth of stock

Less than half of directors are independent

bluebird bio, Inc. Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program

bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor

CEO & Director recently sold Mex$179k worth of stock

bluebird bio, Inc. Announces Updated Results from its Phase 1/2 HGB-206 Study of Lovotibeglogene Autotemcel Gene Therapy

New Data At ASH21, Published in Nejm Further Demonstrate Beti-Cel as A Potentially Curative One-Time Gene Therapy for ß-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Ti and Normal or Near-Normal Adult Hb Levels

Independent Director Wendy Dixon has left the company

Independent Director Wendy Dixon has left the company

Independent Director Wendy Dixon has left the company

Independent Director Wendy Dixon has left the company

Independent Director Wendy Dixon has left the company

Independent Director Wendy Dixon has left the company

Independent Director Wendy Dixon has left the company

Independent Director Wendy Dixon has left the company

Independent Director Wendy Dixon has left the company

Independent Director Wendy Dixon has left the company